GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

The new branding also precedes GSK’s proposed demerger this year, which will mean it focuses entirely on biopharma innovation, while its consumer healthcare business, Haleon, will start life as an ...

In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded analysts ... pure-play since the spin-off of Haleon in July – also raised its ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019.

Haleon misses Q3 forecasts on stronger pound October 31, 2024 GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that ...

Haleon--which owns brands such as Sensodyne toothpaste, Aquafresh mouthwash and over-the-counter medicines Panadol and Advil--was formed in July 2019 through the merger of GSK and Pfizer's ...